Infect Chemother.  2013 Sep;45(3):299-307. 10.3947/ic.2013.45.3.299.

Risk Factors Associated with Group B Streptococcus Resistant to Clindamycin and Erythromycin in Pregnant Korean Women

• Yook JH
• Kim MY
• Kim EJ
• Yang JH
• Ryu HM
• Oh KY
• Shin JH
• Foxman B
• Ki M

• KMID: 2170429
• DOI: http://doi.org/10.3947/ic.2013.45.3.299

Abstract

BACKGROUND
The prevalence of group B streptococcus (GBS) among pregnant women and neonates in the Republic of Korea has increased. In addition, rates of resistance to antibiotics recommended for pregnant women allergic to penicillin, such as clindamycin and erythromycin, have increased. The aim of this study was to evaluate subject characteristics associated with GBS resistance to clindamycin and erythromycin.
MATERIALS AND METHODS
A total of 418 clinical isolates from pregnant women in Korea were screened for antibiotic resistance from January 2006 to December 2011. Sociodemographic information, medical and obstetric history, and details of events during the previous 2 weeks were recorded using a standardized questionnaire.
RESULTS
The resistance rates were 39.5% for clindamycin and 23.0% for erythromycin. In multiple logistic regression analysis, the subject characteristic significantly associated with resistance to both antibiotics was a history of symptomatic sore throat in the 2 weeks before obtaining the specimen (erythromycin: odds ratio [OR]: 2.13, 95% confidence interval [CI]: 1.10 to 4.13; clindamycin: OR: 2.31, 95% CI: 1.21, 4.42). Premature rupture of membranes (PROM) had an association of borderline significance.
CONCLUSIONS
In the urgent treatment of GBS-colonized pregnant women, the subject's history of previous sore throat and PROM should be considered when choosing appropriate antibiotics.

Keyword

Antibiotic resistance; Clindamycin; Erythromycin; Risk factors; Streptococcus agalactiae

MeSH Terms

Anti-Bacterial Agents
Clindamycin
Drug Resistance, Microbial
Erythromycin
Female
Humans
Infant, Newborn
Korea
Logistic Models
Membranes
Odds Ratio
Penicillins
Pharyngitis
Pregnant Women
Prevalence
Republic of Korea
Risk Factors
Rupture
Streptococcus
Streptococcus agalactiae
Anti-Bacterial Agents
Clindamycin
Erythromycin
Penicillins

Reference

1. Baker CJ, Barrett FF. Transmission of group B streptococci among parturient women and their neonates. J Pediatr. 1973; 83:919–925.

2. Yoon HK, Song PJ, Choi KC, Chu CH, Cho BS, Chung SJ. A case of neonatal group B streptococcal meningitis. J Korean Pediatr Soc. 1984; 27:1011–1017.

3. Uh Y, Kwon JY, Jang IH, Yoon KJ, Kim HG. Colonization rate of group B Streptococcus in pregnant women and neonates. Korean J Clin Pathol. 1994; 14:447–453.

4. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep. 2002; 51:1–22.

5. Uh Y, Jang IH, Yoon KJ, Lee CH, Kwon JY, Kim MC. Colonization rates and serotypes of group B streptococci isolated from pregnant women in a Korean tertiary hospital. Eur J Clin Microbiol Infect Dis. 1997; 16:753–756.

6. Kim MW, Jang HO, Chang DY, Cho JR, Kim YA, Choi HM, Kim SH, Lee JP, Hwang KJ, Kang BH. Group B streptococcal colonization rate in Korean pregnant women. Korean J Obstet Gynecol. 2006; 49:337–344.

7. Choi KU, Koh SK, Lee JY, Park JH, Hwang SO, Lee BI, Lee WY. Clinical significance of group B streptococcal infection in pregnant women. Korean J Obstet Gynecol. 2002; 45:811–815.

8. Lee BK, Song YR, Kim MY, Yang JH, Shin JH, Seo YS, Oh KY, Yoon HR, Pai SY, Foxman B, Ki M. Epidemiology of group B streptococcus in Korean pregnant women. Epidemiol Infect. 2010; 138:292–298.

9. Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB, Hadler JL, Danila R, Cieslak PR, Schuchat A. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med. 2000; 342:15–20.

10. Berardi A, Lugli L, Rossi C, Morini MS, Vagnarelli F, Ferrari F. Group B streptococcus and preventive strategies in Europe. Arch Dis Child Fetal Neonatal Ed. 2008; 93:F249.

11. Betriu C, Culebras E, Gómez M, Rodríguez-Avial I, Sánchez BA, Agreda MC, Picazo JJ. Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae. Antimicrob Agents Chemother. 2003; 47:1112–1114.

12. Arisoy AS, Altinişik B, Tünger O, Kurutepe S, Ispahi C. Maternal carriage and antimicrobial resistance profile of group B Streptococcus. Infection. 2003; 31:244–246.

13. Pearlman MD, Pierson CL, Faix RG. Frequent resistance of clinical group B streptococci isolates to clindamycin and erythromycin. Obstet Gynecol. 1998; 92:258–261.

14. Lin FY, Azimi PH, Weisman LE, Philips JB 3rd, Regan J, Clark P, Rhoads GG, Clemens J, Troendle J, Pratt E, Brenner RA, Gill V. Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995-1998. Clin Infect Dis. 2000; 31:76–79.

15. Manning SD, Foxman B, Pierson CL, Tallman P, Baker CJ, Pearlman MD. Correlates of antibiotic-resistant group B streptococcus isolated from pregnant women. Obstet Gynecol. 2003; 101:74–79.

16. Uh Y, Kim HY, Jang IH, Hwang GY, Yoon KJ. Correlation of serotypes and genotypes of macrolide-resistant Streptococcus agalactiae. Yonsei Med J. 2005; 46:480–483.

17. Seo YS, Srinivasan U, Oh KY, Shin JH, Chae JD, Kim MY, Yang JH, Yoon HR, Miller B, DeBusscher J, Foxman B, Ki M. Changing molecular epidemiology of group B streptococcus in Korea. J Korean Med Sci. 2010; 25:817–823.

18. NCCLS. NCCLS document M100-S12. Performance standards for antimicrobial susceptibility testing. Twelfth informational supplement. Wayne, Pa: NCCLS;2002.

19. Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease: a public health perspective. MMWR Recomm Rep. 1996; 45:1–24.

20. Verani JR, McGee L, Schrag SJ. Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010; 59:1–36.

21. Gygax SE, Schuyler JA, Kimmel LE, Trama JP, Mordechai E, Adelson ME. Erythromycin and clindamycin resistance in group B streptococcal clinical isolates. Antimicrob Agents Chemother. 2006; 50:1875–1877.

22. Desjardins M, Delgaty KL, Ramotar K, Seetaram C, Toye B. Prevalence and mechanisms of erythromycin resistance in group A and group B Streptococcus: implications for reporting susceptibility results. J Clin Microbiol. 2004; 42:5620–5623.

23. Schoening TE, Wagner J, Arvand M. Prevalence of erythromycin and clindamycin resistance among Streptococcus agalactiae isolates in Germany. Clin Microbiol Infect. 2005; 11:579–582.

24. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001; 32:Suppl 2. S81–S93.

25. Colodner R, Kometiani I, Chazan B, Raz R. Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli. Infection. 2008; 36:41–45.

26. Arslan H, Azap OK, Ergönül O, Timurkaynak F. Urinary Tract Infection Study Group. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother. 2005; 56:914–918.

27. Kim EJ, Oh KY, Kim MY, Seo YS, Shin JH, Song YR, Yang JH, Foxman B, Ki M. Risk factors for group B streptococcus colonization among pregnant women in Korea. Epidemiol Health. 2011; 33:e2011010.